Carlos Doti: AstraZeneca’s Expanding Impact in Blood Cancer Care
Carlos Doti, VP US Medical Affairs of Oncology at AstraZeneca, shared a post on LinkedIn:
“ASH25 showcased AstraZeneca’s continued growth in hematology.
A decade ago, we presented one abstract. In 2025, we presented 65 abstracts, including:
- 15 oral presentations
- spanning 8 medicines
- 11 diseases
What makes this milestone meaningful isn’t just the science, but how our focus has evolved.
Our responsibility is clear: to help patients have the best quality of life.
As I hear directly from patients, what they want most is freedom from continuous treatment and the chance to return to what truly matters.
Thank you to Mary Caffrey for the opportunity to share these insights and discuss how AstraZeneca is advancing the future of blood cancer care. I encourage you to read the full piece in AJMC – The American Journal of Managed Care.”
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 5, 2026, 05:32Preeti Sinha: Molecular Mechanisms of Atherosclerosis
-
Apr 5, 2026, 05:28Alessandra Bosch: Exploring Haemostasis in Children
-
Apr 5, 2026, 05:19Chris Centeno: Why Regular Blood Therapy Could Boost Aging MSK Health
-
Apr 4, 2026, 18:08Anirban Sen Gupta: Dante Disharoon’s Research on PlateChek Featured on JTH April 2026 Cover
-
Apr 4, 2026, 18:06Domenico Girelli: WHO 2024 Guidelines Reveal Higher Global Anemia Burden and Epidemiological Shift
-
Apr 4, 2026, 18:04Fotios Barkas: Exploring The Bidirectional Relationship Between Frailty and Stroke
-
Apr 4, 2026, 17:56Marc Turner: VETERANSFirst, CHAMPION-AF Trial, and HI-PEITHO Trial Driving Innovation at ACC26
-
Apr 4, 2026, 17:55Julian Kyoung-Ryul Chun: The Largest Dataset on Embolic Complications after AF Is Out
-
Apr 4, 2026, 17:54Marie Dragoy: Insights from Norway on Helicopter Emergency Services in Suspected Stroke Care